Tech Company M&A Transactions
Corvidia Therapeutics Acquisition
Corvidia Therapeutics was acquired by Novo Nordisk. The transaction was announced on 6/11/2020. The companies indicated that total deal value was $2.1 billion.
Transaction Overview
Company Name
Acquired By
Announced On
6/11/2020
Transaction Type
M&A
Amount
$2,100,000,000
M&A Terms
Sofinnova Partners, a leading European life sciences venture capital firm based in Paris, London and Milan, announced today the sale of its portfolio company Corvidia Therapeutics to Novo Nordisk, for $2.1 billion, including an upfront payment of $725 million.
Company Information
Company Status
Acquired or Merged
Industry
Biopharmaceutical
Mailing Address
35 Gatehouse Dr.
Waltham, MA 02451
USA
Waltham, MA 02451
USA
Phone
Website
Email Address
Overview
Corvidia Therapeutics is a biotechnology company pioneering the next generation of cardiovascular therapies. Leveraging functional genomics, the company's founding team has decoded previously unrecognized genetic susceptibilities within general cardiovascular populations.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Marc Garidel
Chief Scientific Officer
Michael Davidson
VP - Bus. Development
Ram Aiyar
VP - Manufacturing
GaoZhong Zhu
VP - Operations
Douglas Kling
VP - R & D
Matthew Devalaraja
Browse more venture capital transactions:
Prev: 6/11/2020: EnsoData venture capital transaction
Next: 6/11/2020: Kyruus venture capital transaction
Share this article
Where The Data Comes From
We do our best to document every notable VC transaction. VC investment data records reported here are sourced from company press releases and news coverage. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs